Previously Recorded
D&O Trends in 2021: Hard Market, COVID-19 and Other Factors Impacting Life Science Companies
Event summary
The range of risk facing executives has increased significantly in recent years, and even before the pandemic, life science companies were more likely to face litigation than other industries. A challenging hard market coupled with heightened risk of lawsuits impact your business in unforeseen ways. As you prepare for investor meetings during the JP Morgan Healthcare Conference, this panel will discuss the trends that will have significant risk implications for senior management in 2021 and beyond.
Cooley partners Koji Fukumura and Kristin VanderPas will speak at this event.
Topics include
- SPAC landscape
- Covid impacts
- Federal forum provisions
- Shareholder litigation
- Officer liability
- Diversity requirements
For more information, please email Deborah Argueta.
Related contacts
This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.